Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 366-371

  Sindos, Michael ^a,b   Ndisang, Daniel ^a   Pisal, Narendra ^b   Chow, Carl ^b   Singer, Albert ^b   Latchman, David S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

Brn 3a transcription factor; Cervical cancer; Gene regulation; Human papillomavirus; Pap smear

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR POU4F1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COLPOSCOPY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UTERINE CERVIX TUMOR; VIRUS STRAIN; WART VIRUS;

EID: 0042123725     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00261-0     Document Type: Article

References (39)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64.
2. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 64. Lyon: International Agency for Research on Cancer; 1995.
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer a worldwide perspective . J Natl Cancer Inst. 85:1995;796-802.
4. Durst M., Gissmann L., Ikenberg H., Zur Hausen H. A papilloma virus DNA from a cervical carcinoma and its prevalence in cancer biopsy sample from different geographic regions. Proc Natl Acad Sci USA. 80:1983;3812-3815.
5. Syrjanen S.M., Syrjanen K.J. New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med. 31:1999;175-187.
6. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 85:1983;958-964.
7. Cox M.F., Meanwell C.A., Maitland N.J., Blackledge G., Scully C., Jordan J.A. Human papillomavirus type-16 homologous DNA in normal human ectocervix. Lancet. 2:1986;157-158.
8. Meanwell C.A. HPV16 DNA in normal and malignant cervical epithelium implications for the aetiology and behaviour of cervical neoplasia . Lancet. 1:1987;703-707.
9. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus. Nature. 393:1998;229-234.
10. Cripe T.C., Hangen T.H., Turk J.P., Tabatabai F., Schmid P.G., Duerst M., et al. Transcriptional regulation of the human papilloma virus-16 E6-E7 promoter by a keratinocyte-dependent enhancer and by viral E 2 transactivator and repressor gene products implications for cervical carcinogenesis . EMBO J. 6:1987;3745-3753.
11. Gloss B., Bernard H.U., Seedorf K., Klock G. The upstream regulatory region of the human papilloma virus contains an E2 protein independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J. 6:1987;3735-3743.
12. Dent C.L., McIndoe G.A.J., Latchman D.S. The constitutively expressed octamer binding protein OTF-1 and a novel octamer binding protein expressed specifically in cervical cells bind to an octamer-related sequence in the human papillomavirus 16 enhancer. Nucleic Acids Res. 19:1991;4531-4535.
13. Morris P.J., Dent C.L., Ring C.J.A., Latchman D.S. The octamer-binding site in the HPV16 regulatory region produces opposite effects on gene expression in cervical and non-cervical cells. Nucleic Acids Res. 21:1993;1019-1023.
14. Gerrero M.R., McEvilly R.J., Turner E., Lin C.R., O'Connell S., Jenne K.J., Hobbs M.V., Rosenfeld M.G. Brn-3.0 A POU domain protein expressed in the sensory, immune and endocrine systems that functions on elements distinct from known octamer motifs. Proc Natl Acad Sci USA. 90:1993;10841-10845.
15. Lillycrop K.A., Budhram-Mahadeo V.S., Lakin N.D., Terrenghi G., Wood J.N., Polak J.M., Latchman D.S. A novel POU family transcription factor is closely related to Brn-3 but has a distinct expression pattern in neuronal cells. Nucleic Acids Res. 20:1992;5093-5096.
16. Turner E.E., Jenne K.J., Rosenfeld M.G. Brn-3.2 A Brn-3-related transcription factor with distinctive central nervous system expression and regulation by retinoic acid . Neuron. 12:1994;205-218.
17. Verrijzer C.P., Van der Vliet P.C. POU domain transcription factors. Biochim Biophys Acta. 1173:1993;1-21.
18. Wegner M., Drolet D.W., Rosenfeld M.G. POU-domain proteins structure and function of developmental regulators . Curr Opin Cell Biol. 5:1993;488-498.
19. Theil T., McLean-Hunter S., Zornig M., Möröy T. Mouse Brn-3 family of POU transcription factors a new amino terminal domain is crucial for the oncogenic activity of Brn-3a . Nucleic Acids Res. 21:1993;5921-5929.
20. Morris P.J., Theil T., Ring C.J.A., Lillycrop KA, Möröy T., Latchman D.S. The opposite and antagonistic effects of the closely related POU family transcription factors on the activity of a target promoter are dependent upon differences in the POU domain. Mol Cell Biol. 14:1994;6907-6914.
21. Lillycrop K.A., Liu Y.Z., Theil T., Moroy T., Latchman D.S. Activation of the herpes simplex virus immediate-early gene promoters by neuronally expressed POU family transcription factors. Biochem J. 307:1995;581-584.
22. Latchman D.S. Regulation of DNA virus transcription by cellular POU family transcription factors. Rev Med Virol. 9:1999;31-38.
23. Ndisang D., Budhram-Mahadeo V.S., Latchman D.S. The Brn-3a transcription factor plays a critical role in regulating HPV gene expression and determining the growth characteristics of cervical cancer cells. J Biol Chem. 274:1999;28521-28527.
24. Ndisang D., Budhram-Mahadeo V., Pedley B., Latchman D.S. The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo. Oncogene. 20:2001;4899-4903.
25. Ndisang D., Morris P.J., Chapman C., Ho L., Singer A., Latchman D.S. The HPV activating transcription factor Brn-3a is overexpressed in CIN3 lesions. J Clin Invest. 101:1998;1687-1692.
26. Ndisang D., Budhram-Mahadeo V.S., Singer A., Latchman D.S. Widespread elevated expression of the HPV-activating cellular transcription factor Brn-3a in the cervix of women with CIN3. Clin Sci. 98:2000;601-602.
27. Reid R., Stanhope C.R., Herschman B.R., Crum C.P., Agronow S.J. A colposcopic index for differentiating subclinical papillomavirus infection from cervical intraepithelial neoplasia. Am J Obstet Gynecol. 149:1984;815-823.
28. Reid R., Scalzi P. An improved colposcopic index for differentiating benign papillomavirus infections from high-grade cervical intraepithelial neoplasia. Am J Obstet Gynecol. 153:1985;611-618.
29. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
30. Shingleton H.M., Patrick R.L., Johnston W.W., Smith R.A. The current status of the Papanicolaou smear. CA Cancer J Clin. 45:1995;305-320.
31. Koss L.G. Accuracy of diagnosis. Cancer. 64:(suppl.):1989;249-252.
32. Al-Nafussi A.I., Colquhoun M.K., Williams A.R. Accuracy of cervical smears in predicting the grades of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 3:1993;89-93.
33. Manos M.M., Kinney W.K., Hurley L.B., Sherman M.E., Shieh-Ngai J., Kurman R.J., et al. Identifing women with cervical neoplasia using Human Papillomavirus DNA testing for Equivocal Papanicolaou results. JAMA. 281:1999;1605-1610.
34. Richard R.M., Cox J.T., Davey D.D., Wright T.C. Bethesda 2001 how the new Pap terminology will impact clinical practice . Contemp Obstet Gynecol. 46:2001;15-43.
35. Ho G.Y.F., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papilloma virus infection in young women. N Engl J Med. 338:1998;423-428.
36. Nobbenhuis M.A.E., Walboomers J.M.M., Helmerhorst T.J.M., Rozendaal L., Remmink A.J., Risse E.K.J., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening a prospective study . Lancet. 354:1999;20-25.
37. Miller A.B. Natural history of cervical human papillomavirus infections. Lancet. 357:2001;1816-2001.
38. Woodman C.B.J., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women a longitudinal cohort study . Lancet. 357:2001;1831-1836.
39. Clavel C., Masure M., Bory J.-P., Putaud I., Mangeonjean C., Lorenzato M., et al. Hybrid Capture ii-based human papillomavirus detection, a sensitive test to detect routine high-grade cervical lesions a preliminary study on 1518 women . Br J Cancer. 80:2001;1306-1311.